Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 6/20 | 0.73 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.73 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.73 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.73 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.73 |
| ▸ | NPY2R | P49146 | 12/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29500562 | 0.93 | CALCR (0.68) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| Calcitonin Salmon SCHEMBL29360745 | 0.92 | CALCR (0.69) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| Elcatonin SCHEMBL29361233 | 0.91 | CALCR (0.64) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| Elcatonin SCHEMBL30495930 | 0.91 | CALCR (0.64) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| Davalintide SCHEMBL29377013 | 0.89 | RAMP1 (0.85) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| SCHEMBL30888738 | 0.87 | NPY2R (0.63) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| Calcitonin Salmon SCHEMBL29392873 | 0.86 | INSR (0.64) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| Calcitonin Salmon SCHEMBL269785 | 0.86 | INSR (0.64) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| SCHEMBL31692974 | 0.86 | RAMP1 (0.82) | CALCRRAMP1RAMP2RAMP3CALCRL | |
| Calcitonin Human SCHEMBL29387864 | 0.86 | CALCR (0.68) | CALCRRAMP1RAMP2RAMP3CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188473-A1 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | claimed |
| US-12123001-B2 | Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| EP-3463350-B1 | PYRROLO-PYRIDINES AND PYRROLO-PYRIMIDINES FOR USE IN TREATING LIVER FIBROSIS | CHEMOCENTRYX INC (US) | 2023-09-13 | — | — | EP | claimed |
| US-20220313668-A1 | METHOD OF TREATING LIVER FIBROSIS | CHEMOCENTRYX INC (US) | 2022-10-06 | — | — | US | claimed |
| US-11357760-B2 | Method of treating liver fibrosis | CHEMOCENTRYX, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4721816-A1 | ENZYMES CAPABLE OF REDUCING SUCCINATE LEVELS AND USES THEREOF | Fundació Institut d'Investigació Sanitària Pere Virgili (IISPV) (ES) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4346822-B1 | COMPOUND AND COMPOSITION FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | GILEAD SCIENCES INC (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3983064-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
| CN-114206884-A | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | 吉利德科学公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-114026104-A | COT modulators and methods of use thereof | 吉利德科学公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | CALCR 3945/4885RAMP1 3795/4885RAMP2 2995/4885 |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | CALCR 1499/4885RAMP1 1497/4885RAMP2 1750/4885 |
| US-20220313668-A1 | METHOD OF TREATING LIVER FIBROSIS | CCR2, CMKLR2, CCL2 | CALCR 1631/4885RAMP1 920/4885RAMP2 189/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CALCR 4164/4885RAMP1 1660/4885RAMP2 1573/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | CALCR 3316/4885RAMP1 2019/4885RAMP2 1950/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | CALCR 1043/4885RAMP1 800/4885RAMP2 1413/4885 |
| US-11357760-B2 | Method of treating liver fibrosis | CCR2, CMKLR2, CCL2 | CALCR 1631/4885RAMP1 920/4885RAMP2 189/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | CALCR 143/4885RAMP1 289/4885RAMP2 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.